Understanding potential effects helps you respond appropriately
Another lever available to employers to manage costs is to limit GLP-1 reimbursement to employees
The other complicating factor can be patients who really cant afford to lose weight (yes this is a real factor in some patients a rarity - but common in my patients) - so there we need to go with a less potent GLP and then look at Rx of Trulicity, but then dose splitting to keep costs down, and still give a decent brain level
The research was led by Isaac Harris, an associate professor in the Department of Biomedical Genetics, and colleagues including co-first authors Fabio Hecht and Marco Zocchi, both in the Harris Lab
If this pans out, were looking at a new chapter in metabolic medicine, one that could deliver sustained weight loss and better long-term outcomes for patients
How long should someone stay on a peptide